Physician profile
Michael Kalus
NPI 1992796890
$4,696.52
in general payments reported to CMS, 2019-2025
23 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $276 · 2021: $727 · 2022: $421 · 2023: $1,217 · 2024: $1,060 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $773.07 | 2019-2025 | Vigilant X4 Crt-D, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals Lp | $605.44 | 2020-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $383.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.18 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $375.00 | 2022-2023 | Arexvy |
| Amgen INC. | $338.71 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $337.32 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $274.90 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $189.98 | 2021 | |
| Pfizer INC. | $177.42 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $175.76 | 2021-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $131.37 | 2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $125.00 | 2024 | |
| Merck Sharp & Dohme LLC | $118.51 | 2023-2024 | Verquvo |
| Scpharmaceuticals INC. | $68.00 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $63.47 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $46.70 | 2023-2025 | Injectafer |
| Kestra Medical Technology Services, INC. | $31.78 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $31.72 | 2024-2025 | Onpattro |
| Medtronic, INC. | $23.74 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $17.24 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $16.40 | 2023 | Arcalyst |
| Cvrx, INC. | $8.29 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kalus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.